Iterion Therapeutics Announces Promising Phase 1b Data for Tegavivint in Combination with Osimertinib in First-Line EGFR-Mutated Non-Small Cell Lung Cancer

HOUSTON, Sept. 22, 2026 /PRNewswire/ — Iterion Therapeutics , a clinical-stage biopharmaceutical company dedicated to advancing the treatment of Wnt-driven cancers, today announced promising results from an investigator-sponsored Phase 1b study conducted at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute evaluating tegavivint in combination with osimertinib as first-line therapy for patients with metastatic EGFR-mutated non-small cell lung cancer (NSCLC). The study, NCT04780568 , is led by principal investigator Regan Memmott, M.D., Ph.D., of the Ohio State University Comprehensive Cancer Center.

The release as fetched from its publisher. iteriontherapeutics.com ↗